000			nab a22 7a 4500
999			_c17227 _d17227
003			PC17227
005			20230213135042.0
008			230213b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9560 _aAbradelo de Usera, Manuel _eCirugía General y Aparato Digestivo
245	0	0	_aPegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. _h[artículo]
260			_bJournal of hepatology, _c2015
300			_a62(1):92-100.
500			_aFormato Vancouver: Castells L, Rimola A, Manzardo C, Valdivieso A, Montero JL, Barcena R et al; FIPSE LT-HIV Investigators. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. J Hepatol. 2015 Jan;62(1):92-100.
501			_aPMID: 25127748
504			_aContiene 38 referencias
505			_aErratum in: J Hepatol. 2016 Mar;64(3):757
520			_aBackground & aims: The aim of this study was to evaluate the results of treatment with pegylated interferon and ribavirin for the recurrence of hepatitis C after liver transplantation in HCV/HIV-coinfected patients. Methods: This was a prospective, multicentre cohort study, including 78 HCV/HIV-coinfected liver transplant patients who received treatment for recurrent hepatitis C. For comparison, we included 176 matched HCV-monoinfected patients who underwent liver transplantation during the same period of time at the same centres and were treated for recurrent hepatitis C. Results: Antiviral therapy was discontinued prematurely in 56% and 39% (p = 0.016), mainly because of toxicity (22% and 11%, respectively; p=0.034). Sustained virological response (SVR) was achieved in 21% of the coinfected patients and in 36% of monoinfected patients (p = 0.013). For genotype 1, SVR rates were 10% and 33% (p = 0.002), respectively; no significant differences were observed for the other genotypes. A multivariate analysis based on the whole series identified HIV-coinfection as an independent predictor of lack of SVR (OR, 0.17; 95% CI, 0.06-0.42). Other predictors of SVR were donor age, pretreatment HCV viral load, HCV genotype, and early virological response. SVR was associated with a significant improvement in survival: 5-year survival after antiviral treatment was 79% for HCV/HIV-coinfected patients with SVR vs. 43% for those without (p = 0.02) and 92% vs. 60% in HCV-monoinfected patients (p < 0.001), respectively. Conclusions: The response to pegylated interferon and ribavirin was poorer in HCV/HIV-coinfected liver recipients, particularly those with genotype 1. However, when SVR was achieved, survival of coinfected patients increased significantly.
710			_9271 _aServicio de Cirugía General y del Aparato Digestivo
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17227.pdf _ySolicitar documento
942			_2ddc _cART _n0